Back

Comparative efficacy and safety of novel biodegradable polymer sirolimus-eluting stents versus permanent polymer everolimus-eluting stents at 5-year follow-up

27 August 2017 (17:24 - 17:33)
Organised by:
Congress Presentation Part of: Optimised myocardial revascularisation strategies PCI / stents: devices and technique ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Roisin Colleran

Mater Private Network, Dublin 7 (Ireland)

8 More presentations in this session

Presentation thumbnail
Five-year outcomes of bifurcation stenting: insights from the SYNTAX trial
Doctor M. Spaziano (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Burden and causes of rehospitalisations following coronary artery bypass grafting: a nationwide study
Mr J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Bilateral internal mammary artery in situ versus Y-graft: mid-term results
Miss F. Saraiva (Porto, PT)
Abstract
Presentation thumbnail
Rate of very late stent thrombosis differs between drug-eluting stents: a 5-year pooled landmark analysis of the SORT OUT III, IV, and V trials
Doctor M. Maeng (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Adherence to cardiac surgical waitlist guidelines is a poor predictor of cardiac surgery waitlist mortality
Doctor J. Senaratne (Edmonton, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Optimised myocardial revascularisation strategies

The Event

Event poster

ESC Congress 2017

27 August 2017 17:24 CET
You may be interested in
thumbnail
Congress Presentation
A novel sirolimus-coated balloon versus a paclitaxel-coated balloon for coronary artery disease: the SELSEQ registry
20 February 2026
thumbnail
Congress Presentation
Group discussion.
29 August 2022
thumbnail
Congress Presentation
Bioresorbable vascular scaffolds - a single center experience
9 March 2024
thumbnail
Congress Presentation
Comparison of two iterations of the zotarolimus-eluting stents: an analysis of all-comer patients from two consecutive randomised clinical trials
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources